Insider Trading disclosures for Tempest Therapeutics Inc

The latest disclosure was made by Justin Trojanowski in Tempest Therapeutics Inc where a trade of 30,000 Employee Stock Option (right to buy) done was reported to US exchanges on Jan. 2, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Justin Trojanowski	Corporate Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	30,000	30,000	-		-	Employee Stock Option (right to buy)
Nicholas Maestas	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	200,000	200,000	-		-	Employee Stock Option (right to buy)
Samuel Whiting	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	270,000	270,000	-		-	Employee Stock Option (right to buy)
Stephen R. Brady	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Jan 2025	550,000	550,000	-		-	Employee Stock Option (right to buy)
Stephen R. Brady	Director, President and CEO	Purchase of securities on an exchange or from another person at price $ 2.11 per share.	03 Jul 2024	35,000	46,376	-	2.1	73,850	Common Stock
Samuel Whiting	Chief Medical Officer	Purchase of securities on an exchange or from another person at price $ 2.13 per share.	02 Jul 2024	4,672	9,573	-	2.1	9,951	Common Stock
Justin Trojanowski	Corporate Controller	Purchase of securities on an exchange or from another person at price $ 2.16 per share.	28 Jun 2024	7,500	22,168	-	2.2	16,200	Common Stock
Christine A. Pellizzari	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	16,000	16,000	-		-	Stock Option (right to buy)
Geoffrey M. Nichol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	16,000	16,000	-		-	Stock Option (right to buy)
Michael G. Raab	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	16,000	16,000	-		-	Stock Option (right to buy)
Ronit Simantov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	16,000	16,000	-		-	Stock Option (right to buy)
Brady Stephen R.	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2024	250,000	250,000	-		-	Employee Stock Option (right to buy)
Justin Trojanowski	Principal Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2024	26,500	26,500	-		-	Employee Stock Option (right to buy)
Nicholas Maestas	VP of Strategy and Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2024	40,000	40,000	-		-	Employee Stock Option (right to buy)
Samuel Whiting	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2024	100,000	100,000	-		-	Employee Stock Option (right to buy)
Geoffrey M. Nichol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	8,200	8,200	-		-	Stock Option (right to buy)
Christine A. Pellizzari	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	8,200	8,200	-		-	Stock Option (right to buy)
Michael G. Raab	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	8,200	8,200	-		-	Stock Option (right to buy)
Ronit Simantov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	8,200	8,200	-		-	Stock Option (right to buy)
Nicholas Maestas	VP of Strategy and Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	38,425	38,425	-		-	Employee Stock Option (right to buy)
Thomas W. Dubensky	Director, President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	102,700	102,700	-		-	Employee Stock Option (right to buy)
Stephen R. Brady	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	177,300	177,300	-		-	Employee Stock Option (right to buy)
Samuel Whiting	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	69,700	69,700	-		-	Employee Stock Option (right to buy)
Justin Trojanowski	Corporate Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	20,300	20,300	-		-	Employee Stock Option (right to buy)
Justin Trojanowski	Corporate Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Oct 2022	2,500	2,500	-		-	Employee Stock Option (right to buy)
Samuel Whiting	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2022	55,680	55,680	-		-	Stock Option (Right to Buy)
Nicholas Maestas	VP of Strategy and Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jun 2022	51,270	51,270	-		-	Stock Option (Right to Buy)
Pierre Lorenzo	Corporate Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jun 2022	8,477	8,477	-		-	Stock Option (Right to Buy)
Thomas W. Dubensky	Director, President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jun 2022	87,801	87,801	-		-	Stock Option (Right to Buy)
Stephen R. Brady	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jun 2022	173,533	173,533	-		-	Stock Option (Right to Buy)
Geoffrey M. Nichol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2022	3,500	3,500	-		-	Stock Option (Right to Buy)
Ronit Simantov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2022	3,500	3,500	-		-	Stock Option (Right to Buy)
Thomas Woiwode	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2022	3,500	3,500	-		-	Stock Option (Right to Buy)
Michael G. Raab	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2022	3,500	3,500	-		-	Stock Option (Right to Buy)
Christine A. Pellizzari	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2022	3,500	3,500	-		-	Stock Option (Right to Buy)
Thomas Woiwode	Director, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 2.36 per share.	29 Apr 2022	2,118,644	2,118,644	-	2.4	5,000,000	Common Stock
Thomas W. Dubensky	Director, President	Purchase of securities on an exchange or from another person at price $ 4.78 per share.	07 Jan 2022	2,000	113,343	-	4.8	9,560	Common Stock
Samuel Whiting	Chief Medical Officer	Purchase of securities on an exchange or from another person at price $ 4.80 per share.	06 Jan 2022	1,700	1,901	-	4.8	8,168	Common Stock
Nicholas Maestas	VP of Strategy and Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Jan 2022	19,500	19,500	-		-	Stock Option (Right to Buy)
Pierre Lorenzo	Corporate Controller	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Jan 2022	6,500	6,500	-		-	Stock Option (Right to Buy)
Samuel Whiting	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Jan 2022	29,000	29,000	-		-	Stock Option (Right to Buy)
Stephen R. Brady	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Jan 2022	94,500	94,500	-		-	Stock Option (Right to Buy)
Thomas W. Dubensky	Director, President	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Jan 2022	53,100	53,100	-		-	Stock Option (Right to Buy)
Michael G. Raab	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Sep 2021	6,635	6,635	-		-	Stock Option (Right to Buy)
Ronit Simantov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Aug 2021	6,635	6,635	-		-	Stock Option (Right to Buy)
Nicholas Maestas	VP of Strategy and Finance	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Jul 2021	23,225	23,225	-		-	Stock Option (Right to Buy)
Thomas Woiwode	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2021	6,635	6,635	-		-	Stock Option (Right to Buy)
Christine A. Pellizzari	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2021	6,635	6,635	-		-	Stock Option (Right to Buy)
Geoffrey M. Nichol	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2021	6,635	6,635	-		-	Stock Option (Right to Buy)
Stella Xu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2021	6,635	6,635	-		-	Stock Option (Right to Buy)

Showing 1 to 50 of 74 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

86.33% Fall from 52W High

Insider Trading disclosures for Tempest Therapeutics Inc

The latest disclosure was made by Justin Trojanowski in Tempest Therapeutics Inc where a trade of 30,000 Employee Stock Option (right to buy) done was reported to US exchanges on Jan. 2, 2025.

Screeners based on Insider Trading and SAST parameters